Growth Metrics

Staar Surgical (STAA) Gains from Sales and Divestitures (2021 - 2026)

Staar Surgical's Gains from Sales and Divestitures history spans 6 years, with the latest figure at $20000.0 for Q1 2026.

  • For Q1 2026, Gains from Sales and Divestitures rose 100.0% year-over-year to $20000.0; the TTM value through Jan 2026 reached $20000.0, up 100.0%, while the annual FY2026 figure was $20000.0, 100.0% up from the prior year.
  • Gains from Sales and Divestitures reached $20000.0 in Q1 2026 per STAA's latest filing, roughly flat from $20000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $127000.0 in Q3 2024 to a low of $4000.0 in Q2 2023.
  • Average Gains from Sales and Divestitures over 5 years is $40625.0, with a median of $20000.0 recorded in 2025.
  • Peak YoY movement for Gains from Sales and Divestitures: plummeted 92.98% in 2023, then surged 3075.0% in 2024.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $5000.0 in 2022, then changed by 0.0% to $5000.0 in 2023, then skyrocketed by 100.0% to $10000.0 in 2024, then skyrocketed by 100.0% to $20000.0 in 2025, then changed by 0.0% to $20000.0 in 2026.
  • Per Business Quant, the three most recent readings for STAA's Gains from Sales and Divestitures are $20000.0 (Q1 2026), $20000.0 (Q3 2025), and $16000.0 (Q2 2025).